

ENROLLMENT/EVALUATION FORM

Psoriasis/Psoriatic Arthritis Grand Rounds

St. Vincent's East
Birmingham, Alabama
PSO170-08

PLEASE PRINT CLEARLY

I am a: ☐ Physician ☐ Pharmacist ☐ Nurse ☐ Advanced Practice Nurse
☐ Physician Assistant ☐ Other Healthcare Professional

First Name <input type="radio"/> Dr. <input type="radio"/> Mr. <input type="radio"/> Ms.	MI	Last Name
Primary Specialty (IM, PC, CD, Endo)	Degree(s)	NPI Number
Affiliation		
Street Address 1 <input type="radio"/> Home <input type="radio"/> Work		
Street Address 2		
City	State/Province	ZIP or Postal Code
Phone Number <input type="radio"/> Home <input type="radio"/> Work <input type="radio"/> Cell	E-mail Address (Required)	
Fax Number	DOB (MM/DD)	NABP ID
Required for Pharmacists only		

Attestation of time spent on activity:

<input type="checkbox"/> I participated in the entire activity and claim 1.0 credit(s).	<input type="checkbox"/> I participated in only part of the activity and claim _____ credits. (Please fill in blank!)	(Note: Partial credit is not available for pharmacists.)
---	---	--

Scale: 4=Excellent; 3=Good; 2=Fair; 1=Poor

Using the above scale, please rate the faculty member on the criteria listed	Ability to effectively convey the subject matter	Ability to present scientifically rigorous information
Danila, Maria I., MD, MSc, MSPH	④ ③ ② ①	④ ③ ② ①

Please evaluate by marking the appropriate response	Excellent	Good	Fair	Poor
Objectivity and balance	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Did you perceive any bias or commercialism towards any product or drug in this activity?	<input type="radio"/> No		<input type="radio"/> Yes	
If yes, please explain _____				

Please evaluate by marking the appropriate response	Excellent	Good	Fair	Poor
Quality of educational content	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Quality of educational materials	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Effectiveness of teaching method used	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Appropriateness and effectiveness of active learning strategies (questions, cases, discussion, etc)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

See reverse side

Learning Objectives

Please rate the following objectives to indicate if you are better able to	Strongly Agree	Agree	Disagree	Strongly Disagree
Outline the immunologic pathways that contribute to the skin and joint manifestations of psoriasis and psoriatic arthritis	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Compare and contrast available therapies, their targets, and clinical application	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Discuss patient-specific factors that may inform selection of therapy across the disease course to ensure response	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Critically assess the mechanisms of action, efficacy, and safety of emerging therapies for psoriasis and psoriatic arthritis	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Please rate the importance of your reasons for attending this educational activity:	Extremely	Very	Not Very	Not at All
Topics	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
CME/CPE credit	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Please rate the projected impact of this activity on your knowledge, competence, performance and patients' outcomes¹:

	Yes	No	Validated Practice	If yes, please describe:
This activity increased my knowledge.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	
This activity increased my competence. ²	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	
This activity will improve my performance.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	
This activity will improve my patient outcomes.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	

1 The Accreditation Council for CME requires us to analyze changes in learners' knowledge, competence, performance, or patient outcomes.

2 Competence is defined as the ability to apply knowledge, skills, and judgment in practice (knowing how to do something).

Please identify how you will change your practice as a result of attending this activity (select all that apply).

- ☐ Change in diagnostic and assessment protocols for psoriasis. Please specify: _____
- ☐ Change in diagnosis/assessment protocols, and/or referral procedures for psoriasis/psoriatic arthritis and/or co-morbid conditions (eg, depression, cardiovascular disease, diabetes). Please specify: _____
- ☐ Other change – please specify: _____
- ☐ This activity validated my current practice; no changes will be made

Please indicate any barriers you perceive in implementing these changes.

- ☐ Lack of administrative support ☐ Lack of consensus or professional guidelines ☐ Cost
- ☐ Lack of experience ☐ Lack of time to assess/counsel patients ☐ No barriers
- ☐ Lack of opportunity (patients) ☐ Reimbursement/insurance issues ☐ Other, please specify: _____
- ☐ Lack of resources (equipment) ☐ Patient compliance issues

Will you attempt to address these barriers in order to implement changes in your competence, performance, and/or patients' outcomes?

- ☐ Yes – How? _____
- ☐ No – Why not? _____
- ☐ N/A - No barriers identified

The content of this activity matched my current (or potential) scope of practice:

- ☐ Yes ☐ No. If no, please explain: _____

Number of patients with psoriasis, psoriatic arthritis, or related inflammatory conditions seen per month:

- ☐ 0 ☐ 1-10 ☐ 11-20 ☐ 21-50 ☐ > 50

What topic areas would you like to see in future activities?

- ☐ Psoriasis and depression ☐ Cardiovascular issues in PsO/PsA ☐ Therapeutic pipeline in PsO/PsA
- ☐ Biosimilars in PsO/PsA ☐ Other: _____

What is one pearl you took away as a result of your participation?

Post-test Questions

Please wait to complete until after the presentation.

1. How confident are you in recognizing the signs and symptoms of psoriasis and/or psoriatic arthritis among patients typically seen in your practice?
 - a. Not at all confident
 - b. Somewhat not confident
 - c. Somewhat confident
 - d. Very confident

2. What is the approximate likelihood that patients with more severe psoriasis (>10% BSA) will die in the next 5 years (via all-cause mortality) compared to the general population?
 - a. At least 5 times (5X) more likely
 - b. At least 1.5 times (1.5X) more likely
 - c. At least 2 times (2X) more likely
 - d. There is no statistically significant difference in mortality

3. Psoriasis patients with >10% BSA are at increased risk of morbidity and mortality from major adverse cardiac events (MACEs), renal disease, liver disease, and other myriad factors. Meanwhile, psoriatic arthritis (PsA) patients also have a higher risk of MACE compared to the general population. Within this clinical context, which one of the following statements is also true?
 - a. TNF- α inhibitors are approximately six times as effective as methotrexate at preventing MACE in patients with psoriasis
 - b. Depression and/or suicidal ideation are not statistically significant causes of morbidity and mortality in the PsO/PsA population.
 - c. Adalimumab, etanercept, and infliximab are all therapies which are safe to use without restriction in PsA patients with cardiovascular comorbidities such as CHF.
 - d. NSAIDs should be considered carefully in patients with pre-existing heart disease and may generally be avoided if possible.

4. Which of the following are signs/symptoms of PsA which may also be a sign of concurrent axial disease (termed psoriatic spondylitis or ankylosing spondylitis)?
 - a. Dactylitis (aka "sausage digit") of the fingers and/or toes
 - b. Low back or gluteal stiffness when getting out of a car, or morning stiffness in the lower back/lower body area lasting ≥ 45 min.
 - c. Psoriatic nail dystrophy
 - d. Radiographic evidence of juxta-articular new bone formation of the peripheral joints

See reverse side.

5. Which of the following statements regarding psoriasis and adverse cardiovascular events has been proven true based on clinical evidence?

- a. Therapeutic intervention in psoriasis directly results in reduced cardiovascular risk of major adverse events.
- b. Systemic inflammation is a common pathway associated with atherosclerosis, psoriasis, obesity, and insulin resistance/metabolic syndrome.
- c. Epidemiological studies have determined that psoriasis patients taking a TNF- α inhibitor (TNFi) had lower rates of major CV events compared with the MTX patient cohort at all timepoints.
- d. Currently available clinical evidence is inadequate to establish a correlation between cardiovascular risk of major adverse events and psoriasis.

6. Case Question: Patient NCD received a PsO diagnosis 5 years ago; with BSA coverage >50%. She received a standard dose of adalimumab 4.5 years ago after initial treatment failure with MTX. Adalimumab failed after 6-months, which was followed by a 6-month course of etanercept along with diet and exercise counseling. At the 6-month etanercept checkup the dermatologist notices in addition to increased BSA involvement, the knuckles of NCD's right-hand middle and ring fingers are showing signs of joint swelling and articular distortion. NCD reports she is sad, unable to concentrate, and no longer enjoys her reading hobby. Her bowel habits are normal and she is adhering to dietary recommendations. Which of the following is the BEST clinical course of action for the dermatologist to take with this patient?

- a. Keep the patient on etanercept for another 6 weeks to gauge treatment safety and efficacy.
- b. Keep the patient on etanercept for another 6 weeks to gauge treatment safety and efficacy, and refer the patient for mental-health evaluation and treatment.
- c. Refer the patient for evaluation by a rheumatologist, discuss the possibility of switching to secukinumab therapy given the failure of two anti-TNFs; also refer the patient for mental health evaluation and treatment.
- d. Restart original course of methotrexate therapy and refer the patient to an occupational therapist for treatment of the new hand joint pain and articular distortion symptoms.

7. Which of the following therapies is an oral medication with a mechanism(s) of action that targets the phosphodiesterase-4 (PDE-4) pathway?

- a. apremilast
- b. secukinumab
- c. ustekinumab
- d. methotrexate

First Name	<input type="radio"/> Dr. <input type="radio"/> Mr. <input type="radio"/> Ms.	MI	Last Name
<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>

I am a: ☐ Physician ☐ Pharmacist ☐ Nurse ☐ Advanced Practice Nurse
☐ Physician Assistant ☐ Other Healthcare Professional

Attendance Roster

Instructor:

Dr. Maria Danila

Credits: 1.00

☒ Direct Sponsored

☐ Jointly Sponsored

Date: March 6, 2018

☒ Inter-professional ☐ Single Discipline

Please Check One: ☐ St. Vincent's Birmingham ☐ St. Vincent's Blount ☐ St. Vincent's Chilton
☒ St. Vincent's East ☐ St. Vincent's St. Clair ☐ St. Vincent's One Nineteen ☐ External ☐ Other:

Name (Please Print)	Hospital/Ministry/ Business	(Pharmacy) DOB & NABP #	Check That Apply
			<input type="checkbox"/> MD <input type="checkbox"/> DO <input type="checkbox"/> NP <input type="checkbox"/> PA <input type="checkbox"/> RN <input type="checkbox"/> Pharmacist <input type="checkbox"/> RPh <input type="checkbox"/> Pharmacy Tech <input type="checkbox"/> OT <input type="checkbox"/> PT <input type="checkbox"/> Social Worker <input type="checkbox"/> Student <input type="checkbox"/> Other
			<input type="checkbox"/> MD <input type="checkbox"/> DO <input type="checkbox"/> NP <input type="checkbox"/> PA <input type="checkbox"/> RN <input type="checkbox"/> Pharmacist <input type="checkbox"/> RPh <input type="checkbox"/> Pharmacy Tech <input type="checkbox"/> OT <input type="checkbox"/> PT <input type="checkbox"/> Social Worker <input type="checkbox"/> Student <input type="checkbox"/> Other
			<input type="checkbox"/> MD <input type="checkbox"/> DO <input type="checkbox"/> NP <input type="checkbox"/> PA <input type="checkbox"/> RN <input type="checkbox"/> Pharmacist <input type="checkbox"/> RPh <input type="checkbox"/> Pharmacy Tech <input type="checkbox"/> OT <input type="checkbox"/> PT <input type="checkbox"/> Social Worker <input type="checkbox"/> Student <input type="checkbox"/> Other
			<input type="checkbox"/> MD <input type="checkbox"/> DO <input type="checkbox"/> NP <input type="checkbox"/> PA <input type="checkbox"/> RN <input type="checkbox"/> Pharmacist <input type="checkbox"/> RPh <input type="checkbox"/> Pharmacy Tech <input type="checkbox"/> OT <input type="checkbox"/> PT <input type="checkbox"/> Social Worker <input type="checkbox"/> Student <input type="checkbox"/> Other
			<input type="checkbox"/> MD <input type="checkbox"/> DO <input type="checkbox"/> NP <input type="checkbox"/> PA <input type="checkbox"/> RN <input type="checkbox"/> Pharmacist <input type="checkbox"/> RPh <input type="checkbox"/> Pharmacy Tech <input type="checkbox"/> OT <input type="checkbox"/> PT <input type="checkbox"/> Social Worker <input type="checkbox"/> Student <input type="checkbox"/> Other
			<input type="checkbox"/> MD <input type="checkbox"/> DO <input type="checkbox"/> NP <input type="checkbox"/> PA <input type="checkbox"/> RN <input type="checkbox"/> Pharmacist <input type="checkbox"/> RPh <input type="checkbox"/> Pharmacy Tech <input type="checkbox"/> OT <input type="checkbox"/> PT <input type="checkbox"/> Social Worker <input type="checkbox"/> Student <input type="checkbox"/> Other
			<input type="checkbox"/> MD <input type="checkbox"/> DO <input type="checkbox"/> NP <input type="checkbox"/> PA <input type="checkbox"/> RN <input type="checkbox"/> Pharmacist <input type="checkbox"/> RPh <input type="checkbox"/> Pharmacy Tech <input type="checkbox"/> OT <input type="checkbox"/> PT <input type="checkbox"/> Social Worker <input type="checkbox"/> Student <input type="checkbox"/> Other
			<input type="checkbox"/> MD <input type="checkbox"/> DO <input type="checkbox"/> NP <input type="checkbox"/> PA <input type="checkbox"/> RN <input type="checkbox"/> Pharmacist <input type="checkbox"/> RPh <input type="checkbox"/> Pharmacy Tech <input type="checkbox"/> OT <input type="checkbox"/> PT <input type="checkbox"/> Social Worker <input type="checkbox"/> Student <input type="checkbox"/> Other

Physicians: St. Vincent's Health System is accredited by the Medical Association of the State of Alabama to provide continuing medical education for physicians. Designation Statement: The St. Vincent's Health System designates this live activity for a maximum of see above *AMA PRA Category 1.00 Credit(s)*TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse: Ascension Health is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. Provider Number: P0340. This activity is approved for 1.0 Contact Hours continuing education.

Pharmacists: The St. Vincent's Health System is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Completion of this knowledge-based activity provides for 1.0 contact hour (0.1 CEU) of continuing pharmacy education credit.

Faculty/Course Director/Planners: STVHS has selected all faculty participating in this activity. It is the policy of STVHS that all CME/CE planning committees, faculty, authors, editors, and staff disclose relationships with commercial interests upon nomination or invitation of participation. Disclosure documents are reviewed for potential conflicts of interest and if relevant, they are resolved prior to confirmation of participation. Only those participants who have no conflict of interest or who agreed to an identified resolution process prior to their participation were involved in this activity.

Please scan back for credit to: lisa.davis2@ascension.org (Info must be completely filled out for credit)

Fax: (205) 838-3518